INCY
INCYTE CORP
Nasdaq: INCY · Wilmington, DE · Healthcare
$103.23+2.59 (+2.57%)Closed
Market Cap$20.65B
Cash$3.75Bmost recent
Runwayprofitable
P/E (TTM)16.1EPS $6.41
52-Wk Range$67.26 – $110.57
Avg Volume1.9M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$103.23+73.8%
Pipeline
Drug candidates sponsored by INCYTE · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 4 | ruxolitinib cream | Atopic Dermatitis+7 more | Recruiting | 2026-10-09 | 12 | |
| Phase 3 | Nivolumab | Lung Cancer | Terminated | 2018-05-22past | 1 | |
| Phase 3 | parsaclisib | Myelofibrosis+5 more | Completed | 2023-08-16past | 4 | |
| Phase 2 | Rituximab (RTX) | Diffuse Large B-cell Lymphoma | Completed | 2024-06-21past | 1 | |
| Phase 3 | Povorcitinib | Hidradenitis Suppurativa (HS)+9 more | Recruiting | 2026-09-03 | 8 | |
| Phase 3 | Ruxolitinib | Polycythemia Vera+9 more | Active, not recruiting | 2027-09-30 | 7 | |
| Phase 3 | INCA034176 | Chronic Graft-versus-host-disease | Active, not recruiting | 2028-05-31 | 1 | |
| Phase 3 | INCB161734 | Solid Tumors | Recruiting | 2028-09-15 | 1 | |
| Phase 3 | INCA33890 | CRC (Colorectal Cancer) | Recruiting | 2028-12-29 | 1 | |
| Phase 2 | INCB018424 | Rheumatoid Arthritis | Completed | 2008-09past | 1 | |
| Phase 1 | INCB007839 | Breast Cancer | Terminated | 2011-06past | 1 | |
| Phase 2 | INCB047986 | Rheumatoid Arthritis | Terminated | 2014-08past | 1 | |
| Phase 2 | Epacadostat | Ovarian Cancer+3 more | Terminated | 2017-11-08past | 2 | |
| Phase 1 | MK-3475 | Microsatellite-instability (MSI) High Colorectal Cancer (CRC)+13 more | Completed | 2018-11-26past | 1 | |
| Phase 1 | INCB057643 | Solid Tumors | Terminated | 2019-02-13past | 1 | |
| Phase 1 | Azacitidine | Solid Tumors+2 more | Terminated | 2019-02-15past | 1 | |
| Phase 1 | INCB053914 | Solid Tumors+2 more | Completed | 2020-09-01past | 2 | |
| Phase 1 | INCAGN01876 | Advanced Malignancies+1 more | Completed | 2021-11-09past | 1 | |
| Phase 1 | INCB059872 | Solid Tumors and Hematologic Malignancy | Terminated | 2022-04-14past | 1 | |
| Phase 1 | INCB001158 | Solid Tumors+14 more | Completed | 2022-11-28past | 4 | |
| Phase 2 | INCB054707 | Hidradenitis Suppurativa+3 more | Completed | 2023-06-30past | 3 | |
| Phase 2 | Itacitinib | Plaque Psoriasis+8 more | Completed | 2023-10-13past | 7 | |
| Phase 2 | Ruxolitinib 1.5% cream | Vitiligo | Completed | 2023-12-19past | 1 | |
| Phase 2 | INCB086550 | Non Small Cell Lung Cancer+4 more | Terminated | 2024-03-26past | 1 | |
| Phase 2 | Retifanlimab | Squamous Cell Carcinoma of Anal Canal+12 more | Completed | 2024-05-22past | 6 | |
| Phase 2 | Pemigatinib | Metastatic Urothelial Carcinoma+13 more | Completed | 2024-10-30past | 4 | |
| Phase 1 | INCB099280 | Advanced Solid Tumors+1 more | Active, not recruiting | 2026-07-22 | 2 | |
| Phase 1 | tafasitamab | Non Hodgkins Lymphoma+2 more | Recruiting | 2027-08-29 | 2 | |
| Phase 1 | INCB024360 | Solid Tumors and Hematologic Malignancy | Completed | 2013-05past | 1 | |
| Phase 1 | Pembrolizumab | Colorectal Cancer (CRC)+10 more | Completed | 2019-11-07past | 1 | |
| Phase 1 | INCAGN02385 | Cervical Cancer+16 more | Completed | 2020-10-07past | 1 | |
| Phase 1 | Ruxolitinib phosphate cream | Atopic Dermatitis | Completed | 2020-10-07past | 1 | |
| Phase 1 | INCB099318 | Advanced Solid Tumors+17 more | Terminated | 2024-08-16past | 1 | |
| Phase 1 | Digoxin | Healthy Participants | Completed | 2025-01-15past | 1 | |
| Phase 1 | Ruxolitinib Cream 1.5% | Prurigo Nodularis | Completed | 2025-07-17past | 1 | |
| Phase 1 | INCB160058 | Healthy Participants | Completed | 2025-08-19past | 1 | |
| Phase 1 | INCB081776 | Advanced Solid Tumors | Terminated | 2025-09-10past | 1 | |
| Phase 1 | INCB000631 | Healthy Participants | Terminated | 2025-10-11past | 1 | |
| Phase 1 | INCB123667 | Healthy Participants+2 more | Not yet recruiting | 2027-04-13 | 2 | |
| Phase 1 | INCA035784 | Myeloproliferative Neoplasms | Recruiting | 2028-03-14 | 1 | |
| Phase 1 | INCA033989 | Myeloproliferative Neoplasms | Recruiting | 2028-10-29 | 1 | |
| N/A | Unnamed | MPN (Myeloproliferative Neoplasms) | Completed | 2019-08-03past | 1 | |
| N/A | Unnamed | BCR-ABL Positive Acute Lymphoblastic Leukemia | Withdrawn | 2021-03past | 1 | |
| N/A | Unnamed | Chronic Myeloid Leukemia | Completed | 2022-12-31past | 1 | |
| N/A | Unnamed | DLBCL - Diffuse Large B Cell Lymphoma | Recruiting | 2025-06-30past | 1 | |
| N/A | INCB054329 | n/a | No Longer Available | — | 1 | |
| N/A | axatilimab | Chronic Graft Vs. Host Disease | Available | — | 1 | |
| N/A | Iticitinib | Aplastic Anemia | No Longer Available | — | 1 | |
| N/A | INCB052793 | n/a | No Longer Available | — | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for INCY. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.